[Eprosartan mesylate in controlling of blood pressure in patients with ischemic stroke].
In 20 patients with ischemic stroke and moderate or severe arterial hypertension the effectiveness of eprosartan mesilat (Teveten, Solway Farma, Germany) for a period of 6 months was studied. Patients received 600 mg of eprosartan mesilat daily and in 4 cases hydrochlortyaside was also added. Monotherapy with eprosartan mesilat was effective in all patients with moderate arterial hypertension and in 43.6% in patients with severe arterial hypertension. Therapy with eprosartan mesilat was associated with significant hypotensive effect (more evident in patients with high systolic blood pressure), improvement in 24-hour blood pressure profile and quality of life, and lower probability of secondary stroke. Side effects were not observed.
Martynov
M Iu
MIu
Boĭko
A N
AN
Petukhov
E B
EB
Berezov
V P
VP
Maskarov
A N
AN
Gusev
E I
EI
D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001921:Brain / Q000098:blood supply; D002545:Brain Ischemia / Q000209:etiology*; D002560:Cerebrovascular Circulation / Q000502:physiology; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000175:diagnosis / Q000517:prevention & control*; D007093:Imidazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D013876:Thiophenes / Q000008:administration & dosage / Q000627:therapeutic use*
D000959:Antihypertensive Agents; D007093:Imidazoles; D013876:Thiophenes; C401803:eprosartan mesylate dihydrate